The analyses revealed that kaempferol, quercetin, and stigmasterol are the main active compounds of the JPYF II Formula used for COPD treatment, and AKT1, IL-6, and TNF are the potential target gene proteins. This evidence concerns the gene IL6 and chronic obstructive pulmonary disease.